Press Releases | DEA.gov
Pasar al contenido principal
U.S. flag

Un sitio oficial del Gobierno de Estados Unidos

Así es como usted puede verificarlo

Dot gov
Los sitios web oficiales usan .gov
Un sitio web .gov pertenece a una organización oficial del Gobierno de Estados Unidos.
Https

Los sitios web seguros .gov usan HTTPS
Un candado ( Candado Un candado cerrado ) o https:// significa que usted se conectó de forma segura a un sitio web .gov. Comparta información sensible sólo en sitios web oficiales y seguros.

  • Quiénes somos
    • Sobre la DEA
    • Mission
    • Leadership
    • Nuestra historia
    • Divisiones Nacionales
      • Operational Divisions
    • DEA Museum
    • Wall of Honor
    • Contáctenos
      • Submit a Tip
      • Extortion Scam
      • Public Affairs
      • Social Media Directory
  • Recursos
    • Cartels
    • Illegal Online Pharmacies
    • OD Justice
    • Fentanyl Supply Chain
    • Pill Press Resources
    • Recovery Resources
    • Together for Families
    • Ley de Libertad de Información
      • Fee Waiver
    • Publications
    • Galerías Multimedia
    • Programa de Asistencia a Testigos para Víctimas
      • Human Trafficking Prevention

United States Drug Enforcement Administration

  • Recibir Actualizaciones
  • Scam Alert
  • Menú Completo
  • English
  • Español

Main Menu

Explore DEA
  • Quiénes somos
    • Sobre la DEA
    • Mission
    • Leadership
    • Nuestra historia
    • Divisiones Nacionales
    • DEA Museum
    • Wall of Honor
    • Contáctenos
  • Recursos
    • Cartels
    • Illegal Online Pharmacies
    • OD Justice
    • Fentanyl Supply Chain
    • Pill Press Resources
    • Recovery Resources
    • Together for Families
    • Ley de Libertad de Información
    • Publications
    • Galerías Multimedia
    • Programa de Asistencia a Testigos para Víctimas

Press Releases

Advanced Search

Enter Keywords Below

Filter Results

Select To Narrow Search Results

Year

  • 2024 (4)
  • 2023 (4)
  • 2022 (7)
  • 2021 (2)

Subject

  • Drug Trafficking (101)
  • Arrests/Convictions - Major (72)
  • Guilty Plea (43)
  • Guns/Weapons (37)
  • Overdose (35)
  • HIDTA (27)
  • OCDETF/Task Force (25)
  • Synthetic drugs (25)
  • Gangs (22)
  • Seizures (Drugs/Property) (22)
  • Prescription Drugs (21)
  • Task Forces/Task Force Officers (21)
  • Take Back Day (18)
  • Fake Pills (17)
  • Major Law Enforcement Operation (17)
  • Money Laundering (16)
  • Pharmaceuticals/Pharmacists/Physicians (16)
  • Extraditions (8)
  • Outreach/Drug Prevention (7)
  • Prevention/Education - DEA websites GSAD, JTT etc (7)
  • Press Conferences (6)
  • Fentanyl Awareness (4)
  • International/Foreign Operations (4)
  • Public and Media Affairs - also see Congressional Affairs (3)
  • Dark Web- Internet Trafficking (2)
  • Intergovernmental Affairs (2)
  • Counterfeit Pills (1)
  • Narcoterrorism (1)
  • One Pill Can Kill (1)
  • Red Ribbon (1)
  • Terrorism (1)
  • Diversion Division (17)

Drug Name

  • Oxycodone (3)

Field Division

  • New England (35)
  • Washington, DC (34)
  • Seattle (25)
  • New York (23)
  • Chicago (18)
  • Houston (16)
  • Atlanta (13)
  • Miami (10)
  • Sede (10)
  • New Orleans (8)
  • El Paso (7)
  • San Francisco (7)
  • St. Louis (7)
  • Dallas (5)
  • Rocky Mountain (5)
  • Phoenix (4)
  • Los Angeles (3)
  • Omaha (3)
  • Louisville (2)
  • Detroit (1)
  • New Jersey (14)
  • San Diego (3)
Clear All Results
17 Results - Showing 1 to 10
PRESS RELEASE

OptumRx Agrees to Pay $20M to Resolve Allegations that It Filled Opioid Prescriptions in Violation of the Controlled Substances Act

SAN DIEGO – OptumRx Inc., a prescription drug benefit provider, has agreed to pay $20 million to resolve allegations that it improperly filled certain opioid prescriptions in violation of the Controlled Substances Act. The settlement resolves an investigation initiated by the Drug Enforcement Administration (DEA) into whether, between April 2013...
PRESS RELEASE

Palomar Hospital Pays $250,000 for Diverting Fentanyl

SAN DIEGO – Palomar Health, a California public health care district located in San Diego County, has paid $250,000 to resolve allegations of diversion of fentanyl from one of its facilities and failure to keep accurate records for fentanyl. Palomar Health is California’s largest health care district, with campuses in...
PRESS RELEASE

Drug Manufacturer to Pay $2.25 Million to Settle Substances Act Allegations

NEWARK, N.J. – A pharmaceutical manufacturer agreed to pay $2.25 million to resolve allegations that it violated the Controlled Substances Act (CSA), DEA New Jersey Field Division Special Agent in Charge Cheryl Ortiz and U.S. Attorney Philip R. Sellinger announced today The manufacturer, Novel Laboratories Inc. (Novel), a subsidiary of...
PRESS RELEASE

Owner Of New Jersey Company Admits to Evading U.S. Customs Duties and His Company Agrees to a $3.1 Million Settlement Agreement

NEWARK, N.J. – The owner of a New Jersey company today admitted mislabeling hazardous chemicals entering the United States and evading customs duties, DEA New Jersey Field Division Special Agent in Charge Cheryl Ortiz and U.S. Attorney Philip R. Sellinger announced today. George Volpe, 60, of Roseland, New Jersey, owner...
PRESS RELEASE

Passaic County Doctor Charged in Conspiracy to Distribute Opioids

NEWARK, N.J. – A Passaic County, New Jersey, doctor was charged with conspiring to distribute opioids without a legitimate medical reason, Special Agent in Charge of the Drug Enforcement Administration’s (DEA) New Jersey Field Division Cheryl Ortiz and U.S. Attorney Philip R. Sellinger announced. Lisa Ferraro, 65, of Hillsdale, New...
PRESS RELEASE

Toms River Woman Charged with Unauthorized Practice of Medicine, Forgery, Health Care Claims Fraud, and Distribution of a Controlled Dangerous Substance

NEWARK, N.J. – Special Agent in Charge of the Drug Enforcement Administration’s (DEA) New Jersey Division Cheryl Ortiz and Ocean County Prosecutor Bradley D. Billhimer announced that on July 25, 2023, Maria F. Macburnie, aka Marife L. Macburnie, 62, of Toms River, was charged with Practicing Medicine by an Unlicensed...
PRESS RELEASE

Gloucester County Man Admits Healthcare Fraud

CAMDEN, N.J. – A Gloucester County, New Jersey, man today admitted defrauding his employer’s health insurance plan out of more than $4 million by submitting fraudulent claims for medically unnecessary compounded medications, Special Agent in Charge of the Drug Enforcement Administration’s New Jersey Division Cheryl Ortiz and Attorney for the...
PRESS RELEASE

Former Office Manager of New Jersey Medical Practice Admits Conspiring with Doctor to Divert Controlled Substances

NEWARK, N.J. – Acting Special Agent in Charge of the Drug Enforcement Administration’s New Jersey Division Daniel J. Kafafian and U.S. Attorney for the District of New Jersey Philip R. Sellinger announced a former office manager of a New Jersey medical practice admitted conspiring with the doctor who owned the...
PRESS RELEASE

Department of Justice Files Nationwide Lawsuit Against Amerisource Bergen Corp. and Subsidiaries for Controlled Substances Act Violations

NEWARK, N.J. – In a civil complaint filed today, the Department of Justice alleges that AmerisourceBergen Corp. and two of its subsidiaries, AmerisourceBergen Drug Corp. and Integrated Commercialization Solutions LLC (AmerisourceBergen), collectively one of the country’s largest wholesale pharmaceutical distributors and one of the largest companies in America by revenue...
PRESS RELEASE

Doctor and Office Manager Indicted in Scheme to Defraud Medicare, Manufacture and Distribute Fentanyl

SAN DIEGO - Dr. David J. Smith, a pain management physician, and his office manager, Julia Ann Oertle, are charged in a federal grand-jury indictment with perpetuating a long-running scheme to commit healthcare fraud and to manufacture and distribute adulterated fentanyl. Smith made his initial appearance today before U.S. Magistrate...

Paginación

  • Current page 1
  • Page 2
  • Siguiente
  • Última página »
  • Quienes Somos
    • Sobre
    • Contáctenos
    • Museo DEA
  • Recursos
    • Ley de Libertad de Información (FOIA)
    • Publicaciones
    • Galerías Multimedia
    • Programa de Asistencia a Testigos para Víctimas
  • Políticas
    • Accesibilidad, Complementos y Política
    • Políticas Legales y Descargos de Responsabilidad
    • Antidiscriminación y Represalias Acto
    • Política de Privacidad
    • Política de Igualdad de Oportunidades en el Empleo del U.S. DOJ
    • USA.gov
    • Protección de Denunciantes
    • Your Rights as a Federal Employee

United States Drug Enforcement Administration

DEA.gov is an official site of the U.S. Department of Justice
Facebook X LinkedIn Instagram

DEA Contact Center

(202) 307-1000
Contact the Webmaster